Cargando…
Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties
BACKGROUND: The purpose of this study was to investigate some of the possible mechanisms underlying the protective effects of a dipeptidyl peptidase IV (DPP-IV) inhibitor, sitagliptin, on pancreatic tissue in an animal model of type 2 diabetes mellitus (T2DM), the Zucker Diabetic Fatty (ZDF) rat, fo...
Autores principales: | Mega, Cristina, Vala, Helena, Rodrigues-Santos, Paulo, Oliveira, Jorge, Teixeira, Frederico, Fernandes, Rosa, Reis, Flávio, de Lemos, Edite Teixeira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998187/ https://www.ncbi.nlm.nih.gov/pubmed/24650557 http://dx.doi.org/10.1186/1758-5996-6-42 |
Ejemplares similares
-
Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)
por: Mega, Cristina, et al.
Publicado: (2011) -
Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
por: Mega, Cristina, et al.
Publicado: (2017) -
Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals
por: Marques, Catarina, et al.
Publicado: (2014) -
Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)
por: Ferreira, Liliana, et al.
Publicado: (2010) -
The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?
por: Godinho, Ricardo, et al.
Publicado: (2015)